Latest News

Active Surveillance After Complete Response to Chemotherapy May Be Effective in Bladder Cancer

Active Surveillance After Complete Response to Chemotherapy May Be Effective in Bladder Cancer

Many patients are cured of all disease (pT0) post-chemotherapy and may be able to defer invasive surgery if properly identified.

Prophylactic Cranial Irradiation Reduces the Incidence of Brain Metastases in NSCLC

Prophylactic Cranial Irradiation Reduces the Incidence of Brain Metastases in NSCLC

Some figures show that incidence of brain metastasis is approximately 30% 2 years after being diagnosed with non-small cell lung cancer.

Noninvasive Exhaled Breath Test May Be Effective In Diagnosing Esophagogastric Cancers

Noninvasive Exhaled Breath Test May Be Effective In Diagnosing Esophagogastric Cancers

Oesophagogastro duodenoscopy is a diagnostic procedure to diagnose esophagogastric cancer, but is highly invasive and expensive.

Sex Hormone Levels Significantly Affect Treatment-Free Survival in Chronic Lymphocytic Leukemia

Sex Hormone Levels Significantly Affect Treatment-Free Survival in Chronic Lymphocytic Leukemia

Men have approximately double the incidence rate, are more likely to have progressive and treatment-resistant disease, and have a poorer prognosis compared with women with CLL.

Reducing Dose Intensity May Be Associated with Shortened PFS in Waldenstrom Macroglobulinemia

Reducing Dose Intensity May Be Associated with Shortened PFS in Waldenstrom Macroglobulinemia

The impact of dose-intensity reduction in Waldenstrom macroglobulinemia has not been explored.

Bladder Cancer, UTUC More Common in Kidney Transplant Recipients

Bladder Cancer, UTUC More Common in Kidney Transplant Recipients

A study found that bladder cancer and UTUC occurred in 122.22 and 113.97 per 100,000 persons per year, respectively, among kidney transplant recipients.

Prostate Cancer Recurrence Risk Lower With Anterior Tumors

Prostate Cancer Recurrence Risk Lower With Anterior Tumors

Following laparoscopic radical prostatectomy, men with posterior index tumors had 76% increased risk of biochemical recurrence vs those with anterior prostate tumors.

Active Surveillance May Be Safe for Selected Men With Gleason 3+4 Prostate Cancer

Active Surveillance May Be Safe for Selected Men With Gleason 3+4 Prostate Cancer

Men with Gleason 6 and Gleason 3+4 prostate cancer who undergo radical prostatectomy after a period on active surveillance have similar surgical outcomes.

Relative Survival for AYAs Comparable to General Population After 7 Years

Relative Survival for AYAs Comparable to General Population After 7 Years

Survivorship plans for adolescent and young adult survivors need to consider the relative long-term survival for AYAs with certain cancers. Those with certain cancers may have excess long-term mortality.

Diabetes Ups Kidney Cancer Risk in Women

Diabetes Ups Kidney Cancer Risk in Women

Women with type 2 diabetes have a 1.5-fold higher risk of renal cell carcinoma compared with non-diabetic women.

Mentally, Physically Demanding Jobs May Predict Unemployment After Breast Cancer Surgery

Mentally, Physically Demanding Jobs May Predict Unemployment After Breast Cancer Surgery

Understanding various factors associated with unemployment may help to guide breast cancer management to increase the rate of returning to work.

Interim PET Scans May Predict Survival Outcomes in Non-Hodgkin Lymphoma

Interim PET Scans May Predict Survival Outcomes in Non-Hodgkin Lymphoma

Being able to identify which patients would respond to standard therapies allows for early adjustment in treatment and improves outcomes.

Cabozantinib Effective in Real-World Analysis for Relapsed Metastatic Renal Cell Carcinoma

Cabozantinib Effective in Real-World Analysis for Relapsed Metastatic Renal Cell Carcinoma

The phase 3 METEOR study previously demonstrated that cabozantinib significantly improved survival outcomes among patients with relapsed renal cell carcinoma.

Oncologists May Not Be Adequately Informed About Medical Marijuana

Oncologists May Not Be Adequately Informed About Medical Marijuana

There is a lack of robust data regarding medical marijuana for oncologists to base clinical decisions and discussions with patients.

Timely Reporting of Palliative Care Needs Leads to More Appropriate End-of-Life Care in NSCLC

Timely Reporting of Palliative Care Needs Leads to More Appropriate End-of-Life Care in NSCLC

Researchers accessed the French National Hospital registry and obtained the records of 64,950 patients who died of metastatic NSCLC between 2010 and 2013.

Neoadjuvant Dose-Dense Gemcitabine, Cisplatin May Be an Ideal Regimen in Bladder Cancer

Neoadjuvant Dose-Dense Gemcitabine, Cisplatin May Be an Ideal Regimen in Bladder Cancer

Various aspects of optimal treatment, such as optimal dose, drug combination, number of cycles, and duration of therapy have yet to be clearly defined for patients with bladder cancer.

Rituximab, Gemcitabine, Plus Oxaliplatin May Be an Effective First-Line Option in Elderly DLBCL

Rituximab, Gemcitabine, Plus Oxaliplatin May Be an Effective First-Line Option in Elderly DLBCL

Rituximab, gemcitabine, plus oxaliplatin has shown high efficacy with low toxicity among elderly patients with relapsed/refractory diffuse large b-cell lymphoma in previous studies.

Osimertinib Improves Quality-of-Life and Global Health Status in Non-Small Cell Lung Cancer

Osimertinib Improves Quality-of-Life and Global Health Status in Non-Small Cell Lung Cancer

Non-small cell lung cancer largely remains incurable and is associated with high symptom burden and reduced quality of life.

FDA Approves Daratumumab/VMP Combination as First-Line Therapy in Multiple Myeloma

FDA Approves Daratumumab/VMP Combination as First-Line Therapy in Multiple Myeloma

Daratumumab was previously approved for patients with multiple myeloma who had previously failed 1 or more lines of therapy.

Nilotinib May Improve Rate of Deep Molecular Response in Chronic Myeloid Leukemia

Nilotinib May Improve Rate of Deep Molecular Response in Chronic Myeloid Leukemia

Previous studies have shown that first-line therapy with nilotinib, as well as switching to nilotinib after prolonged imatinib, may lead to higher rates of deep molecular response in chronic myeloid leukemia.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs